Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Kathy MatuszewskaLisa A SantryJacob P van VlotenAmanda W K AuYeungPierre P MajorJack LawlerSarah K WoottonByram W BridleJim PetrikPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
We have shown, for the first time, that NDV, like other oncolytic viruses, is a potent mediator of acute vascular shutdown and that preventing this through vascular normalization can promote regression in a preclinical model of advanced-stage ovarian cancer. This challenges the current focus on induction of intravascular thrombosis as a requisite for successful oncolytic virotherapy.See related commentary by Bykov and Zamarin, p. 1446.